医学
高氨血症
酮发生
内科学
失代偿
代谢紊乱
代谢性酸中毒
回顾性队列研究
儿科
内分泌学
胃肠病学
酮体
新陈代谢
作者
Susan Thompson,Ashley Hertzog,Arthavan Selvanathan,Kiera Batten,Katherine Lewis,Janelle Nisbet,Ashleigh Mitchell,Troy Dalkeith,Kate Billmore,Francesca Moore,Adviye A. Tolun,Beena Devanapalli,Drago Bratkovic,Cathie Hilditch,Yusof Rahman,Michel Tchan,Kaustuv Bhattacharya
出处
期刊:Nutrients
[Multidisciplinary Digital Publishing Institute]
日期:2023-01-19
卷期号:15 (3): 531-531
被引量:1
摘要
3-Hydroxy-3-Methylglutaryl-CoA Lyase (HMGCL) deficiency can be a very severe disorder that typically presents with acute metabolic decompensation with features of hypoketotic hypoglycemia, hyperammonemia, and metabolic acidosis. A retrospective chart and literature review of Australian patients over their lifespan, incorporating acute and long-term dietary management, was performed. Data from 10 patients contributed to this study. The index case of this disorder was lost to follow-up, but there is 100% survival in the remainder of the cases despite several having experienced life-threatening episodes. In the acute setting, five of nine patients have used 900 mg/kg/day of sodium D,L 3-hydroxybutyrate in combination with intravenous dextrose-containing fluids (delivering glucose above estimated basal utilization requirements). All patients have been on long-term protein restriction, and those diagnosed more recently have had additional fat restriction. Most patients take L-carnitine. Three children and none of the adults take nocturnal uncooked cornstarch. Of the cohort, there were two patients that presented atypically—one with fulminant liver failure and the other with isolated developmental delay. Dietary management in patients with HMGCL deficiency is well tolerated, and rapid institution of acute supportive metabolic treatment is imperative to optimizing survival and improve outcomes in this disorder.
科研通智能强力驱动
Strongly Powered by AbleSci AI